NVNONasdaq

enVVeno Medical Corporation

Healthcare·Healthcare·Phase 3·Irvine, CA, United States

enVVeno Medical Corporation (NVNO): 3 pipeline candidates · ~22 mo cash runway. Updated within the last hour.

7.0/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway6.2

22.2 months

Financial Health9.9

D/E 0.10 · 0% dilution

Pipeline Maturity8.5

Lead: Phase 3

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider Signal4.3

0 buys · 1 sell (180d)

A transparent, data-derived signal for enVVeno Medical Corporationacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$7.0M

Cash

$2.6M

Quarterly Burn

$3.2M

Runway

22.2 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Apr 2028
Today~24 mo out
Catalyst within runway

Pipeline (3 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

12

Total value held

$643K

HolderSharesValue
kingdon capital management, l.l.c.36,166$366K
vanguard capital management llc12,574$127K
geode capital management, llc10,455$106K
vanguard fiduciary trust co2,184$22K
blackrock, inc.1,840$19K
wells fargo & company/mn114$1K
vanguard global advisers, llc77$780
morgan stanley76$770
osaic holdings, inc.7$70
group one trading llc2$20

Showing top 10 of 12 institutional holders of enVVeno Medical Corporation. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Mr. Robert A. Berman

Frequently asked questions

How many drug candidates are in enVVeno Medical Corporation's pipeline?

enVVeno Medical Corporation (NVNO) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is enVVeno Medical Corporation's lead drug candidate?

enVVeno Medical Corporation's most advanced tracked candidate is envve (Preclinical) for Severe Chronic Venous Insufficiency (CVI) of the deep venous system of the leg.

What is enVVeno Medical Corporation's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, enVVeno Medical Corporation has approximately 22.2 months of cash runway.

What is enVVeno Medical Corporation's market capitalization?

enVVeno Medical Corporation's market capitalization is approximately $7.0M.

Who is the CEO of enVVeno Medical Corporation?

Mr. Robert A. Berman is the chief executive officer of enVVeno Medical Corporation (NVNO).

Get the full picture on enVVeno Medical Corporation

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.